title: Peripheral antinociception induced by δ-opioid receptors activation, but not μ- or κ-, is mediated by Ca²⁺-activated Cl⁻ channels.
abstract: Studies have demonstrated that the L-arginine/NO/cGMP pathway and the potassium and calcium channels are involved in the mechanisms underlying opioid receptor activation. As additional pathways may participate in the observed antinociceptive effects following opioid exposure, the aim of our study was to determine whether Ca(2+)-activated Cl(-) channels (CaCCs) are involved in peripheral antinociception induced by μ-, δ- and κ-opioid receptor activation. Hyperalgesia was induced by intraplantar injection of prostaglandin E(2) (PGE(2), 2 μg). Nociceptive thresholds to pressure (grams) were measured using an algesimetric apparatus 3h following injection. The μ-opioid receptor agonist morphine (200 μg), δ-opioid receptor agonist (+)-4-[(alphaR)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80, 80 μg), κ-opioid receptor agonist bremazocine (50 μg), CaCCs blocker niflumic acid (8-64 μg), CaCCs blocker 5-Nitro-2-(3-phenylpropylamino) benzoic acid (NPPB, 32-128 μg), nitric oxide donor sodium nitroprusside (SNP, 500 μg) and cGMP exogenous analogs dibutyryl cGMP (db-cGMP, 100 μg) were also administered into the paw. The CaCCs blocker niflumic acid and NPPB partially reversed the peripheral antinociception induced by exposure to the SNC80 in a dose-dependent manner. In contrast, niflumic acid did not modify the antinociceptive effect observed following exposure to morphine or bremazocine. Additionally, the peripheral antinociception induced by the NO donor SNP or by db-cGMP was not inhibited by niflumic acid. These results provide evidence for the involvement of CaCCs in the peripheral antinociception induced by SNC80. CaCCs activation does not appear to be involved when μ- and κ-opioid receptors are activated. In addition, we did not observe a link between CaCCs and the L-arginine/NO/GMPc pathway.
authors: Department of Pharmacology, Institute of Biological Sciences, UFMG, Av. Antônio Carlos, 6627, CEP: 31.270.100, Belo Horizonte, Brazil.
authors: Daniela da Fonseca
authors: Dda F
authors: Pacheco
authors: Cinthia Mara da Fonseca
authors: CM
authors: Pacheco
authors: Igor Dimitri Gama
authors: ID
authors: Duarte
mesh_terms: D000700:Analgesics / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001120:Arginine / Q000378:metabolism; D018118:Chloride Channels / Q000378:metabolism*; D008297:Male; D009544:Niflumic Acid / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism; D009579:Nitrobenzoates / Q000494:pharmacology; D059225:Nociception / Q000187:drug effects; D017933:Peripheral Nervous System / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D017465:Receptors, Opioid, delta / Q000819:agonists / Q000378:metabolism*; D017473:Receptors, Opioid, kappa / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000700:Analgesics; D018118:Chloride Channels; D009579:Nitrobenzoates; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D009569:Nitric Oxide; C058176:5-nitro-2-(3-phenylpropylamino)benzoic acid; D009544:Niflumic Acid; D001120:Arginine